rttnews.comSEP 112 min read$BLCO

Bausch + Lomb Gains CE Mark For SeeLyra Femtosecond Laser

Bausch + Lomb (BLCO) received CE Mark approval for SeeLyra, a femtosecond laser platform for eye surgeries. The system offers precision, mobility, and real-time imaging. The company plans limited European availability soon, with broader rollout in 2027 and regulatory approvals sought globally. BLCO stock closed at $17.55, down 1.35%.

Original reporting

rttnews.com

Published Sep 11, 2026, 3:45 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 11, 2026, 4:29 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefRegulation

Primary signal

$BLCO

Bullish

medium confidence

Mentioned

$BLCO

Relevance

8/10

AlphAI data visualization · based on rttnews.com

Decision brief

The 30-second read

$BLCOBullishMed

Why it matters

Regulatory approval is a key step toward revenue growth, but market adoption will depend on hospital uptake.

Market read

The CE Mark approval could lift BLCO shares as investors price in new European sales potential.

What to watch

Potential supply chain constraints and competition from established laser platforms.

Relevance 8/10Novelty 8/10Timing: today

Background

Bausch + Lomb is expanding its surgical device portfolio; SeeLyra builds on the VICTUS platform.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$BLCOBullishMedium confidence

Context

EU granted CE Mark approval for Bausch + Lomb's SeeLyra femtosecond laser, a new regulatory milestone.

Expected impact

Potential modest upside as investors price in new European market opportunity.

Evidence & confidence

Regulatory clearance is a concrete catalyst; however, commercial rollout is limited initially, so impact may be gradual.

Market effects

Sector

Strengthens the ophthalmic surgical device sector with a new EU‑approved product.

Regional

Boosts Bausch + Lomb's exposure in the European market.

Global

Adds to global competition among femtosecond laser manufacturers.

Counterpoint

What could challenge this read

European approval may not translate to significant sales if reimbursement hurdles persist.

Key entities

company
Bausch + Lomb Corporation
Eye care company developing SeeLyra laser platform.

Read at source ← All news

OCT 7

$BLCOMedAI 8/10

Bausch + Lomb Advances Dry AMD Treatment Development, Ticker BLC

Bausch + Lomb (NYSE: BLCO) announced progress in developing tonabersat (BL1243) for dry age-related macular degeneration, receiving FDA endorsement for a phase 2 trial in 2027. The company's P/S ratio is 1.18x, below its historical median, and it remains unprofitable. Its GF Score is 60, reflecting mixed fundamentals with strengths in valuation and momentum but weaknesses in profitability and financial strength.

gurufocus.com2 min

OCT 6

$BLCOMedAI 8/10

Bausch + Lomb Advances Oral Therapy for Dry AMD, Ticker BLCO

Bausch + Lomb Corp (BLCO) announced progress in developing BL1243, an oral treatment for dry age-related macular degeneration, following a positive FDA meeting. The company plans to start clinical trials in 2027. BLCO's P/S ratio is 1.18, below its historical median, and it has a GF Score of 60/100, indicating mixed financial health. Insider activity and guru holdings show balanced sentiment.

gurufocus.com2 min

OCT 6

$BLCOLow

Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting

Bausch + Lomb (BLCO) announced progress in developing BL1243, an oral treatment for dry age-related macular degeneration (AMD), following a constructive FDA meeting. The FDA supported the initial study design, which will assess safety and behavior in the body. If successful, BL1243 could offer a new treatment option for dry AMD patients. The company plans to initiate clinical trials in 2027.

marketscreener.com2 min

SEP 18

$RAREMed

Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead

Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo

rttnews.com3 min

SEP 11

$BLCOHighAI 8/10

Bausch + Lomb receives CE Mark for SeeLyra laser

Bausch + Lomb (BLCO) received CE Mark approval for SeeLyra, a next-gen femtosecond laser platform for ophthalmic surgeries. It supports cataract, LASIK, and corneal procedures. Limited European launch is planned, with broader availability expected in 2027. The company is seeking approvals in other markets, including the U.S.

grafa.com2 min